Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05848713 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Study acronym: ATTACC-CAP
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 64 → 68 locations
    • Eligibility criteria expanded, about 17 words
    • Collaborators revised (7)
    • Publications: details revised at 1 of 1 entry
  2. Study sites: 62 to 64
    • Collaborators: 6 to 7
    v12
  3. Study sites revised (62)v11
  4. Site details revised at 52 of 62 sitesv10
  5. Study sites: 66 to 62v9
Show 7 earlier versionsHide 7 earlier versions
  1. Site details revised at 15 of 66 sitesv8
  2. Site details revised at 1 of 66 sitesv7
  3. Site details revised at 5 of 66 sitesv6
  4. Study sites: 59 to 66v5
  5. Study sites: 57 to 59
    • Collaborators: 5 to 6
    v4
  6. Site details revised at 16 of 57 sitesv3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2023 to Oct 10, 2023
    • Study sites: 34 to 57
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Trial Details
NCT Number NCT05848713
Lead Sponsor University of Manitoba
Collaborators: Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI, Aurora Clinical Research
Conditions
(from sponsor)		 Community-acquired Pneumonia
Related terms Community-Acquired Pneumonia, Pneumonia
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov